Kairos Pharma Stock Soars 15.56% on ASCO 2025 Data

On June 4, 2025, Kairos Pharma's stock surged by 15.56% in pre-market trading, reflecting significant investor interest and optimism in the company's recent developments.

Kairos Pharma, a leader in oncology therapeutics, has been at the forefront of utilizing structural biology to combat drug resistance and immune suppression in cancer. The company recently presented new data on its investigational small molecule GITR ligand agonist at the ASCO 2025 Annual Meeting, highlighting its potential in cancer immunotherapy.

Additionally, Kairos Pharma showcased promising data on KROS101, demonstrating its dual mechanisms in cancer immunotherapy. This data, presented at ASCO 2025, indicated that KROS101 outperformed TRX518, further solidifying the company's position in the oncology field.